Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and
anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid
tumor malignancy with homozygous deletion of the MTAP gene.